Looking Forward to a GREAT 2020, page-174

Thanks asxwade

From the Article they state
"The big pharmaceutical companies are not investing in antibiotic research because there is not a lucrative market for them. A novel drug needs to be kept for cases of dire necessity, not sold widely. Overuse will mean resistance to it inevitably develops and although the world badly needs the drugs, new classes of antibiotic are difficult to find."


Which is good for Botanix since they have previously shown that despite extensive exposure to cannabidiol BTX1803, MRSA superbugs do not develop resistance.